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EARLY POST-TRANSPLANT WHOLE TUMOR CELL VACCINATION ELICITS
ANTI-TUMOR T CELL RESPONSES IN PATIENTS WITH ADVANCED
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Hainz, U.1, Stevenson, K.2, Ho, V.T.1, Alonso, A.1, Goldstein, N.R.1,
Lokko, N.1, Sievers, Q.1, Brusic, A.M.1, Zhang, W.1, Pasek, M.1,
Zeng, W.1, Choi, J.1, Brown, J.R.1, Canning, C.M.1, Koreth, J.1,
Cutler, C.1, Armand, P.1, Antin, J.H.1, Sasada, T.1, Ritz, J.1,
Dranoff, G.1, Soiffer, R.J.1, Alyea, E.P.1, Wu, C.J.1 1Dana-Farber Can-
cer Institute, Boston, MA; 2Dana-Farber Cancer Institute, Boston, MA
Vaccinationwithwhole leukemia cells early after allogeneic hemato-
poietic stem cell transplantation (HSCT) may facilitate expansion of
anti-tumor responses. We tested this hypothesis by initiating a phase
I study to vaccinate CLL patients between days 30-100 following re-
duced-intensity (RIC)-HSCT. One cycle of 6 vaccines consisted of
1x107 irradiated autologous CLL cells admixed with irradiated K562
bystander cells secreting the cytokine adjuvant GM-CSF. Of 20 en-
rolled patients, 15 initiated vaccination. Four of 20 developed GvHD
before day 45, precluding vaccination. At a median of 21 months fol-
low-up, all vaccinated patients remain disease-free–an improvement,
comparedwith ahistoric relapse rate of 50%at2 years forCLLpatients
undergoing RIC-HSCT at our center. We thus compared T cell im-
mune reconstitution of study subjects with CLL patients who had un-
dergone RIC-HSCTwithout vaccines. Recovery of peripheral CD31
T cell numbers until d100 was similar between vaccinated subjects and
15 transplanted/non-vaccinatedCLLcontrols. Specificity of the recon-
stituted T cells in vaccinated patients, however, was consistently di-
rected against autologous tumor cells. Five of 5 vaccinated patients
demonstrated increased circulating IFN-g secreting CD81 T cells
by ELISPOT against autologous tumor (mean of 516 vs 184 spots/
106 CD81 T cells at d60 (post-vaccine) vs d30 (pre-vaccine)), but not
against autologous hematopoietic cells (PHA blasts, 57 spots/106
CD81 cells, d60) nor autologous non-hematopoietic cells (fibroblasts,
108 spots/106 CD81 cells, d60). In contrast, 5 of 5 controls (1HSCT,
no vaccine) did not have expanded anti-tumor responses at d60 (mean
51 spots/106CD81 cells).Moreover, withGvHD,T cell reactivity de-
veloped against autologous PHA blasts and fibroblasts (mean 438 and
434 spots/106 CD81 cells at d90, respectively). After vaccination, tu-
mor-reactiveCD81Tcellswere consistently polyfunctional, secreting
high levels ofGM-CSF,TNF-a, and IL-2.By limiting dilution,we iso-
latedT cell clones fromPBMCof 4 vaccinated subjects, and confirmed
that 30-50% of T cell clones demonstrated specific recognition of au-
tologous CLL, but not of alloantigen-bearing cells. Our studies reveal
that early post-transplant CLL/GM-K562 vaccination is associated
with induction of immunity against recipient CLL cells, and suggest
that this is an effective strategy for tipping the balance of immunity in
favor of GvL following nonmyeloablative HSCT.HEMATOPOIESIS/MESENCHYMAL CELLS47
PLATELET-LYSATE-EXPANDED MESENCHYMAL STROMAL CELLS FOR
THE TREATMENT OF RESISTANT GvHD
Lucchini, G.1, Dander, E.1, Rovelli, A.1, Balduzzi, A.1, Bonanomi, S.1,
Belotti, D.1, Gaipa, G.1, Perseghin, P.2, Capelli, C.3, Introna, M.3,
Rambaldi, A.3, Biondi, A.1, d’Amico, G.1, Biagi, E.1 1Universita Milano
Bicocca, Ospedale San Gerardo, Monza, Monza e Brianza, Italy; 2Ospe-
dale San Gerardo, Monza, Monza e Brianza, Italy; 3Ospedali Riuniti di
Bergamo, Bergamo, Bergamo, Italy
Mesenchymal stromal cells (MSC) are multipotent cells with im-
munomodulatory properties, capable to escape immune rejection al-
lowing their use in an HLA-mismatched setting.
We describe a multi-centre experience, which started in May 2008
and relied on the use GMP-grade unrelated HLA-disparate donors’
bonemarrow-derivedMSCs, expanded in Platelet-Lysate -containing
medium. 10 pts (4 to 15 years) transplanted for malignant (N5 8) or
non-malignant (N5 2) diseases, received ivMSCs for acute or chronic
grade I-IV GvHD, which was resistant to multiple lines of immuno-
suppression.TwentyMSC infusions were given to 10 pts. Themedian
dose per infusion was 1.2 106/kg. Response to treatment was evalu-ated 28 days after infusion.Overall response (OS) was 75%,with com-
plete response (CR) in 25%of the cases.We further developed a phase
1 study from August 2009 in order to allow an earlier use of MSCs, as
second line treatment after steroid failure. 13 pts (7 adults, 5 pediatric)
aged 1-58 years received iv MSCs infusions for steroid resistant acute
or chronic GvHD grade II-IV. HSCT was performed for malignant
(N5 10) or nonmalignant diseases (N5 3).GvHDpresented as acute
in 11 cases and chronic in 2, it involved a single organ in 7 pts (5 skin, 2
gut) and multiple organs in the other cases. Pts received 2 to 6 MSC
infusions at 1x 106/kg recipient body weight MSCs for each infusion.
OS was 70 %, and CR 30%. None of the patients affected by chronic
GvHDshowedanybenefit.BothskinandgutGvHDpresentedabetter
response rate, skin showing an earlier response (2 to 4 days) compared
to gut (5 to 7 days). Patients with multiple organ involvement showed
aworse response. In all 34 treated pts, no side affects were observed af-
terMSCinfusion.All responder pts could eventually taper ongoing im-
munosuppression. Seven pts presented GvHD recurrence 2-5 months
after infusion. Four pts developed chronic GvHD. 29 out of 34 treated
patients are alive and in complete remission from their disease with an
average follow-up of 15.5 months from MSC infusion (range 2-29
months). One pt is alive with overt relapse of ALL, 1 pt died from
GvHD complications, 3 pts died from infectious diseases. The present
study underlines the safety of PL-expanded MSC use in children and
adults. MSC efficacy seems to be greater in acute than in chronic
GvHD, it represents anoptimal second-line strategy and it could be ef-
fective even after failure of multiple lines of immunosuppression.48
COTRANSPLANTATION OF THIRD PARTY UMBILICAL CORD BLOOD
MESENCHYMAL STEM CELLS TO PROMOTE ENGRAFTMENT IN PEDIATRIC
RECIPIENTS OF UNRELATED DONOR UMBILICAL CORD BLOOD
Lee, S.H.1, Cheuh, H.W.1, Yoo, K.H.1, Sung, K.W.1, Koo, H.H.1,
Kim, D.H.2, Jung, C.W.2, Choi, S.J.3, Oh, W.3, Yang, Y.S.3 1Samsung
Medical Center, Sungkyunkwan University School of Medicine, Seoul,
Korea; 2Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, Korea; 3Biomedical Research Institute, MEDIPOST
Co., Ltd, Seoul, Korea
Background: Graft-promoting effects of mesenchymal stem cells
(MSCs) may be particularly useful for transplants showing delayed
engraftment, such as unrelated umbilical cord blood transplantation
(UCBT). Inherently low immunogenicity of MSCs may open the
possibilities to use universal donor MSCs. We here report the use
of third party UCB-derived MSCs to enhance engraftment and to
prevent rejection in patients undergoing unrelated UCBT.
Methods: Seven patients with high-risk acute leukemia enrolled in
the study and the outcome was compared with 22 historical controls
with high-risk acute leukemia given UCBTwithout MSCs. UCB-de-
rived, ex vivo-expandedMSCswere infused at a target dose of 1 106/
kg in 4 patients and 5  106/kg in 3 patients. On day 0, patients re-
ceived the specified MSC dose just before infusion of the UCB unit.
Results:There was no acute toxicity related to the infusion ofMSCs
andno sign of ectopic tissue formation.Therewere no significant dif-
ferences for age, gender, transplant indication, and number of
CD341 cells and nucleated cells infused between MSC group and
control group. Neutrophil engraftment occurred at a median of 19
days (16-21) forMSCgroup, and at amedian 17 days (13-44) for con-
trol group (P5 0.76). The probability of achieving a platelet count$
20  109/L by 100 days after transplant was 100% at a median of 47
days (33-80) for MSC group, and 76.5% at a median of 51 days (19-
231) for control group (P5 0.41). In comparison to controls (13.6%
graft failure), all patients who were given MSCs engrafted success-
fully. The incidence of grade III-IV acute GvHD was 14.3% for
MSC group and 5.9% for control group (P 5 0.51). The incidence
of extensive chronic GvHD was not statistically different between
MSC (14.3%) and control group (18.8%, P5 0.79). The incidences
of treatment-related mortality (TRM) within 100 days of transplant
and veno-occlusive disease (VOD) were 18.2% and 22.7% in control
group,whereas none of the patients ofMSCgroup experiencedTRM
or VOD. Although there was a trend toward improved 2-year event-
free survival after transplant in MSC group (75.0%) compared with
control group (54.5%), it was not statistically significant (P5 0.33).
S170 Oral PresentationsConclusion: These demonstrated that safety and feasibility of third
party UCB-derived MSCs use and co-infusion of UCB-derived
MSCs can overcome graft dysfunction of UCBT.HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES49
CORD BLOOD (CB) APGAR SCORE IS PREDICTIVE OF NEUTROPHIL
ENGRAFTMENT AND GRAFT FAILURE PROBABILITIES FOR PLASMA
DEPLETED/REDUCED CB PRODUCTS
Chow, R.1,2, Wang, B.C.1, Chou, D.1, Chow, M.1, Wu, T.1, Kang, J.2,
Petz, L.D.1, Kurtzberg, J.3 1StemCyte International Cord Blood Center,
Covina, CA; 2StemCyte Taiwan National Cord Blood Center, Linkou,
Taiwan; 3Duke University Medical Center, Durham, NC
Nucleated cell (NC), CD341 cell (CD34), and colony forming unit
(CFU) doses have been proposed to measure CB potency - important
for engraftment potential prediction and transplantation product selec-
tion.ThoughTNCiswidelyused forCBselection, its predictive value is
not as robust as the progenitor cell measurements. CFU andCD34 suf-
fer from high inter-laboratory coefficient of variance (CV) - decreasing
the clinical utility as potency measures. Recently, the Duke Group pro-
posed a CB APGAR scoring system composed of (a) a Pre-Cryopre-
served Score (PCS) reflecting pre-freeze CFU, CD34, NC, and CB
collected volume, aswell as a (b)Composite Score (CS)which combines
the PCS score with post-thaw NC, CD34, CFU and mononuclear cell
dose. Based on single, myeloablative and first (SMF) transplants of
largely pediatric patients performed at Duke and using mostly red cell
reduced (RCR)CB, the PCS andCS scores were shown to be predictive
of graft failure, neutrophil and platelet engraftment. With CIBMTR-
auditedoutcomedataof transplantedCBproducts fromamulti-national
CBbank,we sought to validate theCBAPGARsystemonapatient pop-
ulationwithmostly adults, heavy representationofminority and interna-
tional patients, and on both SMF transplants, and all transplants (All)
using plasma depleted/reduced (PDR) CB products. The PCS and CS
table below shows the day 42 neutrophil engraftment cumulative inci-
dence (ANC500) and graft failure probability (GF) comparisons of the
Duke data with PDR transplants for both SMF and All transplants.
For each of the PCS and CS strata compared, ANC500 and GF ap-
peared to be similar among theDuke SMF, StemCyte SMF and All co-
horts.We conclude that theCBAPGARscore, especially the PCS, is an
easy-to-use and reproducible potencymeasurement forCB selection by
transplant centers that is highly predictive of ANC500 engraftment and
GF for (1) RCRaswell as PDRCB, (2) formostly pediatric patient pop-
ulationaswell as formixedpopulationsof adults andchildren, and (3) for
minority and international patients.Whether themethod canbe applied
to double, non-myeloablative and repeat CB transplants remains to be
seen.Lastly, for the samePCSorCSstrata,PDRCBappear tohave sim-
ilar engraftment and GF probabilities as RCRCB; therefore, the Duke
CB APGAR is applicable to CB products with or without RBC reduc-
tion and reflects potencyofCBproducts processed and storedby various
methods at different CB banks.
Table 1. ANC 500 Engraftment Cumulative Incidence & Graft
Failure Probabilities
ANC 500 Duke SMF PDR SMF PDR AllPCS$7.75 93% (86-100%) 100±18% 83±19%
PCS<7.75 75% (69-81%) 78±9% 76±4%
HR 2.44 (1.78 - 3.59) 2.43 (0.85 - 6.95) 1.92 (0.78 - 4.68)
CS$13.5 90% (84 - 95%) 94±14% 84±11%
CS<13.5 69% (61 - 78%) 68±12% 77±6%
HR 2.31 (1.73 - 3.08) 1.54 (0.73 - 3.26) 1.19 (0.78 - 1.82)Graft Failure
ProbabilityDuke SMF PDR SMF PDR AllPCS$7.75 7% (3-17%) 0±18% 17±19%
PCS$5.5 & <7.75 19% (12-30%) 15±14% 18±10%
PCS$4.25 & <5.5 26% (16-39%) 6±13% 14±9%
PCS<4.25 32% (22-45%) 38±12% 29±5%50
IN-VIVO EXPANSION OF T REGULATORY CELLS BY RAPAMYCIN IN A
CALCINEURIN-INHIBITOR FREE GVHD PROPHYLAXIS IN UNMANIPU-
LATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION (SCT)
Peccatori, J.1, Clerici, D.1, Forcina, A.1, Bondanza, A.2, Messina, C.1,
Giglio, F.1, Mastaglio, S.1, Crotta, A.1, Lupo Stanghellini, M.T.1,
Marcatti, M.1, Crocchiolo, R.1, Assanelli, A.1, Bernardi, M.1, Corti, C.1,
Noviello, M.2, Olek, S.3, Ferraro, A.4, Battagglia, M.4, Roncarolo, M.G.5,
Locatelli, F.6, Bonini, C.2, Ciceri, F.1 1San Raffaele Scientific Institute, Mi-
lan, Italy; 2San Raffaele Scientific Institute, Milan, Italy; 3Epiontis Gmb,
Berlin, Germany; 4San Raffaele Scientific Institute,Milan, Italy; 5San Raf-
faele Scientific Institute,Milan, Italy; 6 IRCCSOspedale Pediatrico Bambino
Gesu, Roma, Italy
Background:Tregs are attractive candidates for clinical modulation
of excessive immune responses. In SCT mouse models, the adoptive
transfer of purified natural Tregs has been shown to prevent GvHD,
while sparing a significant GvL effect. Tregs’ suppressor function
has been demonstrated to be critically dependent on IL-2, therefore
cyA significantly reduces the function of allostimulated Tregs.
Aim: To address the role of Tregs in human SCT, we focused on
a calcineurin inhibitor-free GvHD prophylaxis. We tested this hy-
pothesis in haploidentical peripheral blood stem cells SCT without
any in-vitro manipulation.
Patients and Methods: Since 2007, 68 pts underwent allo-SCT for
AML (43), ALL (9),MDS (3),MPD (4), NHL (4) orHD (5).Median
age was 48 years (range 14-69). At SCT all but 8 pts were in advanced
phase. Conditioning included Treosulfan (14 g/m2 for 3), Fludara
(30 mg/m2 for 5) and an in-vivo T and B-cell depletion, by ATG-
Fresenius (10 mg/kg for 3) and Mabthera (a single 500 mg dose).
All pts received allogeneic PBSC from an HLA-haploidentical
related donor without any in-vitro positive selection. GvHDprophy-
laxis consisted of Rapamycin (target level 8-15 ng/ml, till day 160)
and MMF (15 mg/kg tid till day 130).
Results: All pts but 3 had neutrophil engraftment. CI of grade 2-4,
grade 3-4 aGvHD and cGvHD were 22%, 11% and 26%. 100 days
TRM and relapse incidence at 1 year were 17% and 44%. Projected
OS at 1 year is 39%. Immunoreconstitution was fast and sustained
with amedian 220 circulatingCD31cells/mLonday130.Wedetected
high levels of CD41CD251CD127- FOXP31 Tregs (up to 30% of
circulating CD41 T lymphocytes) on day 130. These cells were able
to suppress in vitroproliferationof autologous effector cells.Thisobser-
vation was further reinforced at a molecular level.We applied a quanti-
tative RT-PCR based methylation assay that enables a specific and
sensitive determination of T regs numbers by measuring demethylated
FOXP3atT reg specific demethyleted region (TSDR).Anexpansionof
cells carrying FOXP3 demethylation was evident in our pts, but not in
a control group of pts receiving mismatched SCT and cyclosporine.
Conclusions: Rapamycin-Mycophenolate-ATG are effective as
GvHD prophylaxis in unmanipulated haploidentical peripheral SCT
andare associatedwith an earlyT-cell immunoreconstitution character-
ized by the in-vivo expansion of Tregs. Further studies are warranted to
gain insight correlations between Tregs expansion and SCT outcome.
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8/8 HIGH-RESOLUTION HLA MATCH RATE: THE IMPACT OF RACE
Dehn, J.1, Buck, K.1, Yang, S.Y.2, Schmidt, A.3, Hartzman, R.4,
Maiers, M.1, Setterholm, M.1, Confer, D.1 1National Marrow Donor
Program, Minneapolis, MN; 2Histogenetics, Inc., Ossining, NY;
3DKMS, Tuebingen, Germany; 4C.W. Bill Young Marrow Donor Re-
cruitment and Research Program, Rockville, MD
Aim: Calculation of the 8/8 (HLA-A, B, C, DRB1) high-resolution
(HR) match rate using real patient unrelated donor (URD) searches
presents a biased sample for reasons including access to treatment, fi-
nancial barriers and incomplete donor testing. A study was designed
to estimate the truematch rate forCaucasian (CAU),Hispanic (HIS),
Asian/Pacific Islander (API), and African American (AFA) groups,
representing the four largest race groups in the US population.
Methods: 1344 URD searches were performed for pseudopatients
(PP) who were randomly selected, previously HR tested donors in
the NMDP’s Be The Match Registry (BTMR). Searches were based
on a fixed BTMR file as of January 2009. Search results from CAU,
HIS, API, and AFA PP were classified as follows:
